Non-pharmacologic strategies for the management of intestinal inflammation

• Autor(a) principal: Tatiani Uceli Maioli
• Data de Publicação: 2022
• Outros Autores: Luísa Martins Trindade, Aline Souza, Lícia Torres, Maria Emília Rabelo Andrade, Valbert Nascimento Cardoso, Simone de Vasconcelos Generoso
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1016/j.biopha.2021.112414; http://hdl.handle.net/1843/66060; https://orcid.org/0000-0002-7538-3208; https://orcid.org/0000-0001-7597-9602; https://orcid.org/0000-0001-6413-8031
• topic: Intestinal inflammation; Omega-3; Probiotic; Prebiotic; Synbiotic; FODMAP; Doenças inflamatórias intestinais; Ácidos graxos Ômega-3; Probióticos; Prebióticos; Simbióticos; Dieta FODMAP

Inflammatory bowel diseases, irritable bowel syndrome, and mucositis are characterized by intestinal inflammation, but vary according to their pathological mechanisms, severity, location, and etiology. Significant intestinal inflammation that occurs in these diseases induces weight loss, nutritional depletion, and gastrointestinal tract dysfunction. Nutritional support is important in alleviating symptoms and improving patients’ quality of life. In this review, we summarize some nutritional components used to manage intestinal disorders. These include fatty acids, probiotics, parabiotics, postbiotics, prebiotics, synbiotics, and low FODMAP (LFD) diets. These components and LFD diets have been studied and clinical trials have been designed to develop new strategies to alleviate intestinal inflammation and improve the quality of life. Clinical trials on their use in intestinal inflammation do not allow firm conclusions to be drawn mainly because of the heterogeneity of the dose used and the study design or their inconclusive results. However, in the majority of cases, the use of omega-3, probiotics, parabiotics, postbiotics, prebiotics, synbiotics, and LFD improve the health.